All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

BioWorld. Link to homepage.

/images/Cortellis_Flagship_Logo_TM_RGB_Color.png
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Artificial intelligence
    • Coronavirus
    • Diagnosing and tracking COVID-19
    • Drugs to Watch 2020
    • The next pandemic
    • Premium reports
      • BioWorld Financings Reports
      • Disease Forecast Reports

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Saturday, February 27, 2021
Home » Blogs » BioWorld Perspectives » Oh, Give it Iressa! Nope: ‘Bad Pharma’ Firms Need to Tell More

BioWorld Perspectives
BioWorld Perspectives RSS FeedRSS

BioWorld / Cancer / Oncology

Oh, Give it Iressa! Nope: ‘Bad Pharma’ Firms Need to Tell More

June 7, 2013
By Randy Osborne
No Comments

badSo urgently did I think I wanted to read Ben Goldacre’s Bad Pharma, that I ordered it from Amazon’s UK site last November, unwilling to wait for U.S. publication – which happened just as I reached the end, polishing off the book’s afterword, called “Better Data.”

Goldacre, it turns out, is as much bothered by the secrecy of data as by its quality, and he has also set up an activist website, where the public can petition for “all [clinical] trials to be registered, for all summary results to be reported, and for full clinical study reports [CSRs] to be made publicly available,” he writes on his original site, which takes its name from Goldacre’s previous book. “CSRs are important, because it is now clear that brief summaries about trials [such as academic journal articles] can be incomplete or misleading,” writes Goldacre.

I probably took so long to get through the book because I sensed that the heft text would take on “the usual Big Pharma critiques, touching on the ethical morass of human trials and the infuriating dirty tricks pharmaceutical firms use to market their drugs both to patients and to doctors,” as a review in the New York Times pointed out late last month. But there’s more to the book.

Among the firms Goldacre, a London doctor, takes to task is GlaxoSmithKline plc, which surprised the author and probably everyone else in February when the firm came aboard his cause, and agreed to post its CSRs online. “They have also made sensible noises about the practicalities, which shows that they have thought about the implications, and they also discuss prioritizing which CSRs to work on first,” writes Goldacre. (Another reason for my slow going with this book: dread of stiff British, physician-style writing and clichés. Practicalities, implications and prioritizing. “Because [GSK has] discussed these technical details – while I will always wait for the proof in the pudding – I do not believe this is mere lip service,” he goes on, wedging in a couple more.)

But, as a blunt instrument, the book seems to be having an effect. Will AstraZeneca plc join GSK? Goldacre summarily smacks down the developer of Iressa (gefitinib), a rather easy target, in his book. “Large, well-conducted fair tests of Iressa had shown that it was no better than a dummy sugar pill containing no medicine,” he writes, yet patients who turned out at an FDA advisory panel meeting sang the drug’s praises.

“When the committee charged with approving the drug [sic] cast their votes, they went 11-3 in favor,” Goldacre recalls. “We can only wonder if individuals who had not been successfully treated with Iressa would have been flown across the country to speak their personal truth. Perhaps not. Perhaps they might be dead.” Perhaps. But the issue of full trial-data disclosure, thanks to Goldacre’s book, is anything but.

You must login or register in order to post a comment.

Report Abusive Comment

Popular Stories

  • Free access to BioWorld coronavirus articles

    BioWorld

    The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus outbreak. Note that we have added three critical tables which are...

  • Seniors with wooden puzzle

    Cassava’s simufilam improves AD patients’ cognition, behavior

    BioWorld
    When Cassava Sciences Inc.’s president and CEO, Remi Barbier, opened up the interim analysis of the company’s open-label study for Alzheimer’s disease candidate...
  • Vaxart COVID-19 vaccine tablets

    Vaxart shares shaken despite apparently positive early data for oral COVID-19 vaccine

    BioWorld
    Vaxart Inc. investors who stuck by company shares Feb. 3 had to swallow a bitter pill – watching shares of the oral vaccine developer (NASDAQ:VXRT) fall 57.8% to...
  • IPO money

    Lucira Health launches $153M IPO

    BioWorld MedTech
    Infectious diseases diagnostics company Lucira Health Inc. launched an IPO of 9 million shares of common stock at $17 per share, for expected gross proceeds of...
  • Today's news in brief

    BioWorld
    BioWorld briefs for Feb. 26.
cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • About
    • Archives
    • Today's news
    • Search BioWorld Science
  • More
    • About
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
A Clarivate Analytic solution. Link to Clarivate website.
Follow Us

Copyright ©2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing